Nivolumab
Loss of INI 1 Protein Expression
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
34 Active assets in the Loss of INI 1 Protein Expression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tazemetostat Epizyme, Inc. | Phase 2 | BB |
Hycamtin Pfizer | Phase 2 | B |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2 | B |
Palbociclib Pfizer | Phase 2 | B |
Olaparib National Cancer Institute (NCI) | Phase 2 | B |
View all 44 →
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →